Medinol announces successful first-in-human implantation of the ChampioNIR drug-eluting peripheral stent system in Australia

TEL AVIV, Israel, Oct 7, 2024 /PRNewswire/ — Medinol Ltd. is pleased to announce the successful first-in-human (FIH) implantation of the drug-eluting peripheral stent ChampioNIR by Dr Gerard S. Goh and Thodur Vasudevan from Alfred Hospital in Melbourne Australiarepresenting a revolutionary advance in the mechanics, durability and drug delivery of peripheral drug-eluting stents.

The ChampioNIR drug-eluting peripheral stent system represents a transformative technology designed to improve patient outcomes and procedural success. In a first-of-its-kind hybrid mechanical design, radial support is provided by the metal component of the stent, while longitudinal structure is provided by a bioabsorbable polymer mesh, providing unmatched flexibility and long-term durability in even the most challenging anatomies. In addition, a unique drug elution paradigm releases the drug from the entire cylindrical region of the stent, drastically reducing diffusion distances and allowing, for the first time, therapeutic dosing of a “Limus” drug into a large peripheral vessel over an extended period of time.